Abstract:Pompe disease, a deficiency of glycogen-degrading lysosomal acid alpha-glucosidase (GAA), is a disabling multisystemic illness that invariably affects skeletal muscle in all patients. The patients still carry a heavy burden of the disease, despite the currently available enzyme replacement therapy. We have previously shown that progressive entrapment of glycogen in the lysosome in muscle sets in motion a whole series of “extra-lysosomal” events including defective autophagy and disruption of a variety of signa… Show more
“…The entrapment of lysosomal glycogen results in muscle damage by a number of pathogenic mechanisms, such as defective autophagy, calcium homeostasis, oxidative stress, and mitochondrial abnormalities [2]. Recently, metabolic abnormalities and energy deficits have also been shown to contribute to this pathogenic cascade [3]. The severity of clinical manifestations, tissue impairment and age of onset correlate with the residual enzymatic activity and can be classified into two forms: the Infantile Onset Pompe Disease (IOPD) or classical form has no or very low enzymatic activity levels, leading to severe general muscular weakness with floppy infant syndrome.…”
Pompe disease is a multisystemic disorder with the hallmark of progressive skeletal muscle weakness that often results in difficulties in walking and balance. However, detailed characterization of gait and postural regulation with this disease is lacking. The objective of this investigation was to determine if differences exist between the gait and postural regulation of LOPD patients and a matched control group. The gaits of 16 patients with LOPD were assessed using a gait analysis mobile system (RehaGait) and a dynamometric treadmill (FDM-T 1.8). The Interactive Balance System (IBS) was used to evaluate postural regulation and stability. All measures were compared to individual reference data. Demographic (age, gender), morphological (body height, body mass) and clinical data (muscle strength according to the Medical Research Council Scale (MRC Scale), as well as the 6-min walking test and a 10-m fast walk) were also recorded. Compared to individual reference data, LOPD patients presented with reduced gait velocity, cadence and time in single stand. A total of 87% of LOPD patients had abnormalities during posturographic analysis presenting with differences in postural subsystems. This study provides objective data demonstrating impaired gait and posture in LOPD patients. For follow-up analysis and as outcome measurements during medical or physiotherapeutic interventions, the findings of this investigation may be useful.
“…The entrapment of lysosomal glycogen results in muscle damage by a number of pathogenic mechanisms, such as defective autophagy, calcium homeostasis, oxidative stress, and mitochondrial abnormalities [2]. Recently, metabolic abnormalities and energy deficits have also been shown to contribute to this pathogenic cascade [3]. The severity of clinical manifestations, tissue impairment and age of onset correlate with the residual enzymatic activity and can be classified into two forms: the Infantile Onset Pompe Disease (IOPD) or classical form has no or very low enzymatic activity levels, leading to severe general muscular weakness with floppy infant syndrome.…”
Pompe disease is a multisystemic disorder with the hallmark of progressive skeletal muscle weakness that often results in difficulties in walking and balance. However, detailed characterization of gait and postural regulation with this disease is lacking. The objective of this investigation was to determine if differences exist between the gait and postural regulation of LOPD patients and a matched control group. The gaits of 16 patients with LOPD were assessed using a gait analysis mobile system (RehaGait) and a dynamometric treadmill (FDM-T 1.8). The Interactive Balance System (IBS) was used to evaluate postural regulation and stability. All measures were compared to individual reference data. Demographic (age, gender), morphological (body height, body mass) and clinical data (muscle strength according to the Medical Research Council Scale (MRC Scale), as well as the 6-min walking test and a 10-m fast walk) were also recorded. Compared to individual reference data, LOPD patients presented with reduced gait velocity, cadence and time in single stand. A total of 87% of LOPD patients had abnormalities during posturographic analysis presenting with differences in postural subsystems. This study provides objective data demonstrating impaired gait and posture in LOPD patients. For follow-up analysis and as outcome measurements during medical or physiotherapeutic interventions, the findings of this investigation may be useful.
“…Likewise, the mechanism of impaired autophagosomal-lysosomal fusion, which can be directly observed by time-lapse microscopy of live fibers co-stained with LC3/LAMP1 [67], is not fully understood. Our recent finding of increased levels of galectin 3, a sensitive marker of endosomal/lysosomal damage, in KO muscle offers a possible explanation for the defective fusion [66].…”
Section: Beyond the Lysosome: Pathogenic Cascade And Muscle Regenerationmentioning
confidence: 90%
“…In a large preclinical study in KO mice, AT-GAA was shown to significantly outperform alglucosidase alfa in all measured outcomes: GAA uptake and activity, muscle strength, reduction in lysosomal size and glycogen levels, and mitigation of autophagic defect [92]. Furthermore, long-term treatment of KO with AT-GAA completely reversed muscle lysosomal glycogen accumulation, eliminated autophagic buildup in >80% of muscle fibers, and to a large degree restored AMPK/mTORC1 signaling, muscle proteostasis, and metabolic abnormalities [66]. This outcome is in striking contrast with the limited effect of a long-term treatment of KO mice with alglucosidase alfa at a similar dose of 20 mg/kg [22].…”
Section: Next-generation Ertmentioning
confidence: 91%
“…The molecular mechanism underlying the defective autophagy in the diseased muscle involves both increased formation of autophagosomes (induction of autophagy) and their inefficient fusion with lysosomes (autophagic block). Elevated levels of proteins required for the initial steps of autophagy (autophagosome nucleation and maturation), such as VPS15 protein kinase, the lipid kinase catalytic subunit VPS34, and the regulatory protein Beclin1, in muscle biopsies from KO and Pompe patients [65,66] argue for autophagy induction. The mechanism of this surge in autophagy is not exactly clear.…”
Section: Beyond the Lysosome: Pathogenic Cascade And Muscle Regenerationmentioning
confidence: 99%
“…Furthermore, autophagic buildup negatively affects trafficking and lysosomal delivery of the therapeutic enzyme [67][68][69] and contributes to poor skeletal muscle response to ERT [70,71]. Importantly, autophagic accumulation and elevated levels of galectin 3 can be detected as early as in 6-week-old KO mice, well before the disease becomes clinically apparent [66].…”
Section: Beyond the Lysosome: Pathogenic Cascade And Muscle Regenerationmentioning
Pompe disease, also known as glycogen storage disease type II, is caused by the lack or deficiency of a single enzyme, lysosomal acid alpha-glucosidase, leading to severe cardiac and skeletal muscle myopathy due to progressive accumulation of glycogen. The discovery that acid alpha-glucosidase resides in the lysosome gave rise to the concept of lysosomal storage diseases, and Pompe disease became the first among many monogenic diseases caused by loss of lysosomal enzyme activities. The only disease-specific treatment available for Pompe disease patients is enzyme replacement therapy (ERT) which aims to halt the natural course of the illness. Both the success and limitations of ERT provided novel insights in the pathophysiology of the disease and motivated the scientific community to develop the next generation of therapies that have already progressed to the clinic.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.